ASX Announcement: 25 November 2026 (Melbourne, Australia)
Optiscan Imaging Ltd (ASX: OIL)

Optiscan Appoints COO to Accelerate Operational Scale-Up

Strategic appointment strengthens manufacturing, commercial readiness and execution capability as Optiscan advances its next phase of global growth.

HIGHLIGHTS

- Optiscan has appointed Andrew McLellan as Chief Operating Officer, adding dedicated executive leadership to convert the Company's clinical, regulatory and product progress into disciplined commercial execution.
- The appointment strengthens Optiscan's readiness to scale manufacturing, supply chain, quality systems and operational infrastructure in line with anticipated product demand and international expansion.
- Andrew McLellan brings extensive operational leadership experience spanning manufacturing, business scale-up, supply chain, engineering, project management and logistics, together with a strong record of building systems, teams and processes that support reliable growth and product delivery.
- The appointment provides the CEO with additional capacity to concentrate greater focus on corporate strategy, capital markets, product advancement development, clinical programs and regulatory execution delivery.
- The role is expected to increase organisational capacity, improve scalability and strengthen on-time delivery across Optiscan's expanding product portfolio and commercial pipeline.

Optiscan Imaging Limited (ASX:OIL) ('**Optiscan**' or the '**Company**') is pleased to announce the appointment of Andrew McLellan as Chief Operating Officer ('COO'), a strategic addition to the executive leadership team designed to strengthen commercial readiness, accelerate operational scale-up and support consistent delivery through Optiscan's next phase of growth.

Andrew will lead Optiscan's operational functions, with responsibility for growing the manufacturing, supply chain, quality, systems and delivery capabilities required to progress products efficiently from development and regulatory approval into commercial production and market deployment.

The appointment comes as Optiscan advances multiple technologies through regulatory pathways and market-readiness activities. Establishing scalable operating capability at this stage positions the Company

to respond to commercial opportunities with greater speed, reliability and control while maintaining the standards required of a growing medical technology business.

OPERATIONAL SCALE AND COMMERCIAL READINESS

As Optiscan's product portfolio matures, the Company is aligning its operating model with its commercial ambitions. The COO will provide clear executive ownership of the capabilities that underpin successful market entry and growth, including manufacturing readiness, supplier performance, production planning, quality and regulatory alignment, inventory management and customer delivery and service.

As COO, Andrew will lead the Company's Operations Team, taking overall responsibility for Manufacturing, Production, Service, Logistics, Supply Chain, Inventory, Quality, and Regulatory functions. He will also work with engineering, clinical, commercial and corporate functions to translate strategic priorities into executable operating plans, measurable milestones and dependable delivery.

A key priority will be establishing scalable and repeatable processes capable of supporting multiple products, higher production volumes and an expanding international footprint. This operational discipline is expected to reduce execution risk, improve visibility across the delivery chain and enable the Company to pursue growth opportunities from a stronger and more resilient platform.

Across previous senior roles, Andrew has built and scaled operational platforms, established resilient supplier and logistics networks, led multidisciplinary engineering teams and delivered complex projects from planning through implementation. Andrew offers a strong combination of technical product credibility, regulated medtech experience, and commercial judgement. This combination of practical operating experience and growth leadership is closely aligned with Optiscan's manufacturing and commercial scale-up priorities.

EXPERIENCED LEADERSHIP

Andrew is a Melbourne-based mechanical engineer, MBA and ASX-listed former executive with more than 30 years across life sciences, medical devices, advanced manufacturing and deep technology. He has led manufacturing operations, business scale-up, supply-chain development, engineering teams, complex projects and logistics functions, with a focus on improving productivity, quality, capacity and delivery performance.

Prior to joining Optiscan, Andrew led former ASX-listed Bluechiip Ltd for a decade from 2015 to 2025, taking its sample-management platform from core IP through FDA and CE-registered hardware, software and consumables, global commercialisation and an outsourced manufacturing and supply-chain model. More recently, Andrew held an Executive Vice President role with Cryonix Group, following its acquisition of Bluechiip assets.

From 2010 to 2015, at the Advanced Manufacturing Cooperative Research Centre (AMCRC), Andrew led commercialization and subsequently the Centre, a large-scale industry, government and research collaboration focused on advanced manufacturing innovation and commercialization. Prior to that he was Director of Business Unit for Leica Microsystems (2007-2009), and Vice President of Marketing and Business Development at Vision BioSystems (2006-2007), subsequently acquired by Leica. Andrew is currently a Non-Executive Director with the new Additive Manufacturing CRC. Andrew will commence in his new role on 12 January 2027.

CEO COMMENT

Optiscan CEO and Managing Director, Dr Camile Farah, said:

"The appointment of Andrew McLellan as Chief Operating Officer is a strategic investment in Optiscan's ability to convert product and regulatory progress into sustained commercial growth."

"We have made significant progress across technology development, clinical programs and regulatory readiness. The next stage requires equally strong execution in manufacturing, supply chain, quality systems and customer delivery so that we can scale with confidence as commercial opportunities develop."

"Andrew brings deep operational experience across manufacturing, scaling businesses, supply chain, engineering, project management and logistics. His proven ability to build operating capability, coordinate complex delivery programs and translate growth plans into dependable execution will be highly valuable as Optiscan prepares for broader commercialisation."

"This appointment increases our leadership capacity at a pivotal point in Optiscan's evolution. It gives the Company a stronger platform to scale production, support international growth, improve delivery certainty and execute our strategy with greater pace and accountability."

COO COMMENT

Optiscan Incoming COO, Andrew McLellan, said:

"I am excited to be joining Optiscan at such a pivotal time. The Company's recent FDA submissions are a significant achievement and reflect the quality of its technology, its regulatory discipline and the strength of the team. I am looking forward to working with the team to scale Optiscan's operations and manufacturing capabilities in preparation for U.S. commercial launch, and to build the systems, processes and quality foundations needed to deliver reliably for customers as the business grows."

– ends –

This announcement has been authorised for release by the Board of Optiscan.

For further information, please contact:

Shareholder & General Enquiries
Optiscan Imaging Ltd
Dr Camile Farah
T: +61 3 9538 3333
E: ceo@optiscan.com

Media & Investor Enquiries
The Capital Network
Julia Maguire
T: +61 2 7257 7338
E: julia@thecapitalnetwork.com.au

About Optiscan

Optiscan Imaging Ltd (ASX: OIL) is a commercial stage medical technology company creating a suite of digital pathology and precision surgery hardware and software solutions that enable live optical biopsy for life sciences, diagnostic and surgical applications. Optiscan pioneered the development and manufacturing of miniaturised digital endomicroscopes with spatial resolution more than 1000x that of medical CT and MRI.

Using a revolutionary "tissue contact" method, Optiscan's patented technology produces super high-resolution digital pathology images for cancer diagnosis and surgical treatment, to unlock real-time insights during surgery, diagnostics, and pre-clinical research. By enabling live, non-destructive, 3D, in-vivo digital imaging at the single-cell level, Optiscan's technology supports earlier disease detection, precision treatment, and improved patient outcomes across a wide selection of clinical applications and settings.

The global addressable market for Optiscan's medical imaging technology extends beyond traditional surgery and pathology, to also encompass the fast-growing digital health market including robotic surgery. With an expanding product suite and increased demand for digital health solutions, Optiscan is uniquely positioned to bridge the gap between surgery and pathology and deliver better outcomes for healthcare professionals and their patients.

To learn more about Optiscan, visit www.optiscan.com or follow us on LinkedIn, X or Instagram.

Disclaimer

All statements other than statements of historical fact included on this announcement including, without limitation, statements regarding future plans and objectives of Optiscan or any of the other parties referred to herein, are forward-looking statements. Forward-looking statements can be identified by words such as 'anticipate", "believe", "could", "estimate", "expect", "future", "intend", "may", "opportunity", "plan", "potential", "project", "seek", "will" and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions, and on assumptions regarding future events and actions that are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, its directors and management of Optiscan that could cause actual results to differ from the results expressed or anticipated in these statements.